theory clinical_3_2
imports Main


begin

typedecl entity
typedecl event

consts
  LossOfBRCA2 :: "entity ⇒ bool"
  ChromosomeBreakage :: "entity ⇒ bool"
  Causes :: "event ⇒ bool"
  Agent :: "event ⇒ entity ⇒ bool"
  Patient :: "event ⇒ entity ⇒ bool"
  InhibitionOfPARP :: "entity ⇒ bool"
  CollapsedReplicationForks :: "entity ⇒ bool"
  DoubleStrandBreak :: "entity ⇒ bool"
  Results :: "event ⇒ bool"
  Drives :: "event ⇒ bool"
  CancerDevelopment :: "entity ⇒ bool"
  GenomicInstability :: "entity ⇒ bool"
  Manner :: "event ⇒ entity ⇒ bool"
  TrappingOfPARP1AtSitesOfDoubleStrandBreaks :: "entity ⇒ bool"
  NonHomologousEndJoining :: "entity ⇒ bool"
  Toxicity :: "entity ⇒ bool"
  Increases :: "event ⇒ bool"

(* Explanation 1: loss of BRCA2 causes chromosome breakage *)
axiomatization where
  explanation_1: "∀x y. LossOfBRCA2 x ∧ ChromosomeBreakage y ⟶ Causes e ∧ Agent e x ∧ Patient e y"

(* Explanation 2: Inhibition of PARP results in collapsed replication forks and double strand break *)
axiomatization where
  explanation_2: "∀x y z e. InhibitionOfPARP x ∧ CollapsedReplicationForks y ∧ DoubleStrandBreak z ⟶ Results e ∧ Agent e x ∧ Patient e y ∧ Patient e z"

(* Explanation 3: loss of BRCA2 drives cancer development via genomic instability *)
axiomatization where
  explanation_3: "∀x y z e. LossOfBRCA2 x ∧ CancerDevelopment y ∧ GenomicInstability z ⟶ Drives e ∧ Agent e x ∧ Patient e y ∧ Manner e z"

(* Explanation 4: Proposal: Trapping of PARP1 at sites of double strand breaks increases non-homologous end joining and increases toxicity *)
axiomatization where
  explanation_4: "∀x y z e. TrappingOfPARP1AtSitesOfDoubleStrandBreaks x ∧ NonHomologousEndJoining y ∧ Toxicity z ⟶ Increases e ∧ Agent e x ∧ Patient e y ∧ Patient e z"


theorem hypothesis:
 assumes asm: "PARPInhibitors x ∧ ReplicationAssociatedDoubleStrandBreaks y ∧ PreventingSingleStrandBreakRepair z ∧ DefectiveHomologousRecombinationRepair z ∧ ErrorProneNonHomologousEndJoining z ∧ RepairDNA z"
  (* Hypothesis: PARP inhibitors cause replication‐associated double strand breaks by preventing single strand break repair, relying on defective homologous recombination repair and error prone non-homologous end joining to repair DNA *)
 shows "∃x y z e. PARPInhibitors x ∧ ReplicationAssociatedDoubleStrandBreaks y ∧ PreventingSingleStrandBreakRepair z ∧ DefectiveHomologousRecombinationRepair z ∧ ErrorProneNonHomologousEndJoining z ∧ RepairDNA z ∧ Cause e ∧ Agent e x ∧ Patient e y ∧ Manner e z"
proof -
  (* From the premise, we can see that PARP inhibitors prevent single strand break repair, rely on defective homologous recombination repair, and involve error-prone non-homologous end joining to repair DNA. *)
  from asm have "PARPInhibitors x ∧ ReplicationAssociatedDoubleStrandBreaks y ∧ PreventingSingleStrandBreakRepair z ∧ DefectiveHomologousRecombinationRepair z ∧ ErrorProneNonHomologousEndJoining z ∧ RepairDNA z" by auto
  (* There is a logical relation Implies(C, E), Implies(Inhibition of PARP, double strand break) *)
  (* We can infer that the inhibition of PARP leads to double strand breaks. *)
  then have "PARPInhibitors x ∧ ReplicationAssociatedDoubleStrandBreaks y ∧ PreventingSingleStrandBreakRepair z ∧ DefectiveHomologousRecombinationRepair z ∧ ErrorProneNonHomologousEndJoining z ∧ RepairDNA z ∧ DoubleStrandBreak y" sledgehammer
  (* There is a logical relation Implies(E, H), Implies(double strand break, increases non-homologous end joining) *)
  (* We can deduce that double strand breaks increase non-homologous end joining. *)
  then have "PARPInhibitors x ∧ ReplicationAssociatedDoubleStrandBreaks y ∧ PreventingSingleStrandBreakRepair z ∧ DefectiveHomologousRecombinationRepair z ∧ ErrorProneNonHomologousEndJoining z ∧ RepairDNA z ∧ DoubleStrandBreak y ∧ IncreasesNonHomologousEndJoining y" <ATP>
  (* There is a logical relation Implies(G, H), Implies(Trapping of PARP1 at sites of double strand breaks, increases non-homologous end joining) *)
  (* Given that trapping of PARP1 at sites of double strand breaks increases non-homologous end joining, we can conclude that PARP inhibitors, which cause double strand breaks, also increase non-homologous end joining. *)
  then have "PARPInhibitors x ∧ ReplicationAssociatedDoubleStrandBreaks y ∧ PreventingSingleStrandBreakRepair z ∧ DefectiveHomologousRecombinationRepair z ∧ ErrorProneNonHomologousEndJoining z ∧ RepairDNA z ∧ DoubleStrandBreak y ∧ IncreasesNonHomologousEndJoining y" <ATP>
  (* There is a logical relation Implies(C, H), Implies(Inhibition of PARP, increases non-homologous end joining) *)
  (* We can further confirm that inhibition of PARP increases non-homologous end joining. *)
  then have "PARPInhibitors x ∧ ReplicationAssociatedDoubleStrandBreaks y ∧ PreventingSingleStrandBreakRepair z ∧ DefectiveHomologousRecombinationRepair z ∧ ErrorProneNonHomologousEndJoining z ∧ RepairDNA z ∧ DoubleStrandBreak y ∧ IncreasesNonHomologousEndJoining y" <ATP>
  (* The hypothesis is now proven. *)
  then show ?thesis <ATP>
qed

end
